A PK and Safety Study in Subjects With Hepatic Impairment
NCT01431833
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatic Impairment
Interventions
DRUG:
TR-701 FA
Sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)